Lena is VP of Payer Innovation at Alva10dx. Lena has spent her career studying reimbursement and the managed care industry from the perspective of diagnostics.
Leveraging her background in biology and mathematics, Lena is working to match the price of new diagnostics to payer value through improvements in the reimbursement process. Lena most recently led the reimbursement strategy of QIAGEN’s global molecular diagnostics portfolio and has broad experience in diagnostics commercialization, sales, contracting, and reimbursement. Earlier, she held multiple leadership roles at AmniSure International until its successful strategic sale. She has personally performed every step in the reimbursement spectrum of a diagnostic, and takes both a product-specific and portfolio-wide view of the healthcare products she brings to payers. She is passionate about driving reimbursement toward value-based care, and bringing clarity and change to a field that healthcare reform has put into flux.
There is zero consensus on the level of evidence a diagnostic must show in order to prove clinical utility but establishing the right systems for coverage and reimbursement would allow modern diagnostics to drive a future of widespread precision medicine.